Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy | 43 | 2026 | 3266 | 1.950 |
Why?
|
| Diabetes, Gestational | 5 | 2023 | 57 | 1.880 |
Why?
|
| Cesarean Section | 5 | 2022 | 162 | 1.320 |
Why?
|
| Pregnancy Complications | 5 | 2021 | 368 | 1.290 |
Why?
|
| Obesity | 8 | 2022 | 1076 | 1.050 |
Why?
|
| Gestational Age | 9 | 2026 | 342 | 1.000 |
Why?
|
| Obstetrics | 3 | 2018 | 125 | 1.000 |
Why?
|
| Pregnancy Complications, Infectious | 5 | 2026 | 100 | 0.910 |
Why?
|
| Postpartum Period | 3 | 2022 | 169 | 0.880 |
Why?
|
| Placenta | 5 | 2026 | 202 | 0.800 |
Why?
|
| Child Development | 2 | 2026 | 179 | 0.780 |
Why?
|
| Breast Feeding | 3 | 2021 | 113 | 0.740 |
Why?
|
| Cost-Benefit Analysis | 7 | 2015 | 525 | 0.720 |
Why?
|
| Infant, Newborn | 10 | 2025 | 2544 | 0.680 |
Why?
|
| Pre-Eclampsia | 4 | 2025 | 270 | 0.670 |
Why?
|
| Overweight | 2 | 2021 | 128 | 0.670 |
Why?
|
| Female | 47 | 2026 | 51685 | 0.650 |
Why?
|
| Hirschsprung Disease | 1 | 2020 | 13 | 0.640 |
Why?
|
| Tracheal Diseases | 1 | 2020 | 14 | 0.630 |
Why?
|
| Fetal Diseases | 1 | 2020 | 71 | 0.620 |
Why?
|
| Intellectual Disability | 1 | 2021 | 207 | 0.600 |
Why?
|
| Surgical Wound | 1 | 2019 | 7 | 0.600 |
Why?
|
| Tissue Adhesives | 1 | 2019 | 23 | 0.590 |
Why?
|
| Patient Discharge | 1 | 2022 | 381 | 0.590 |
Why?
|
| Labor, Obstetric | 1 | 2019 | 49 | 0.580 |
Why?
|
| Electrocardiography | 1 | 2022 | 528 | 0.580 |
Why?
|
| Pregnancy in Diabetics | 2 | 2022 | 44 | 0.580 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2019 | 59 | 0.580 |
Why?
|
| Hypertension, Pregnancy-Induced | 3 | 2026 | 93 | 0.580 |
Why?
|
| Postpartum Hemorrhage | 2 | 2022 | 28 | 0.570 |
Why?
|
| Abnormalities, Multiple | 1 | 2020 | 235 | 0.570 |
Why?
|
| Health Care Costs | 3 | 2014 | 258 | 0.560 |
Why?
|
| Suture Techniques | 1 | 2019 | 141 | 0.560 |
Why?
|
| Aneuploidy | 2 | 2016 | 60 | 0.530 |
Why?
|
| Prenatal Diagnosis | 2 | 2016 | 107 | 0.510 |
Why?
|
| Physicians, Primary Care | 1 | 2018 | 108 | 0.490 |
Why?
|
| Adult | 32 | 2026 | 29548 | 0.490 |
Why?
|
| Humans | 50 | 2026 | 98223 | 0.470 |
Why?
|
| Health Personnel | 1 | 2018 | 257 | 0.460 |
Why?
|
| Term Birth | 1 | 2015 | 8 | 0.460 |
Why?
|
| Placenta Growth Factor | 3 | 2025 | 85 | 0.460 |
Why?
|
| Anesthesia, Epidural | 1 | 2015 | 34 | 0.450 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 3 | 2025 | 111 | 0.440 |
Why?
|
| Body Mass Index | 7 | 2021 | 867 | 0.420 |
Why?
|
| Prospective Studies | 11 | 2025 | 4815 | 0.410 |
Why?
|
| Cesarean Section, Repeat | 1 | 2014 | 3 | 0.410 |
Why?
|
| Trial of Labor | 1 | 2014 | 6 | 0.410 |
Why?
|
| Labor Stage, Second | 3 | 2022 | 6 | 0.410 |
Why?
|
| Vaginal Birth after Cesarean | 1 | 2014 | 8 | 0.410 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2014 | 45 | 0.400 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 118 | 0.400 |
Why?
|
| Serpins | 2 | 2014 | 31 | 0.380 |
Why?
|
| Nerve Growth Factors | 2 | 2014 | 54 | 0.370 |
Why?
|
| Hepatitis C | 2 | 2005 | 186 | 0.370 |
Why?
|
| Misoprostol | 2 | 2024 | 22 | 0.360 |
Why?
|
| Cohort Studies | 11 | 2026 | 3217 | 0.350 |
Why?
|
| Labor, Induced | 2 | 2024 | 34 | 0.350 |
Why?
|
| Eye Proteins | 2 | 2014 | 131 | 0.350 |
Why?
|
| Glucose Tolerance Test | 2 | 2023 | 239 | 0.350 |
Why?
|
| Cardiotocography | 2 | 2022 | 8 | 0.340 |
Why?
|
| Pregnancy Outcome | 4 | 2024 | 284 | 0.340 |
Why?
|
| Oxytocics | 2 | 2022 | 26 | 0.330 |
Why?
|
| DNA | 1 | 2016 | 1274 | 0.310 |
Why?
|
| Infant | 4 | 2026 | 3348 | 0.300 |
Why?
|
| Hospitalization | 1 | 2015 | 986 | 0.300 |
Why?
|
| Stillbirth | 1 | 2008 | 15 | 0.280 |
Why?
|
| Pregnancy, Twin | 2 | 2026 | 12 | 0.270 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2024 | 70 | 0.260 |
Why?
|
| Quality Improvement | 2 | 2022 | 526 | 0.250 |
Why?
|
| Weight Gain | 3 | 2020 | 138 | 0.250 |
Why?
|
| Retrospective Studies | 11 | 2026 | 11031 | 0.250 |
Why?
|
| Delivery, Obstetric | 2 | 2022 | 120 | 0.230 |
Why?
|
| Logistic Models | 4 | 2026 | 1275 | 0.230 |
Why?
|
| Mass Screening | 3 | 2013 | 750 | 0.220 |
Why?
|
| Adiponectin | 1 | 2025 | 22 | 0.220 |
Why?
|
| Vitamin E | 1 | 2025 | 34 | 0.220 |
Why?
|
| Ascorbic Acid | 1 | 2025 | 41 | 0.220 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2026 | 62 | 0.220 |
Why?
|
| Fetal Blood | 1 | 2025 | 95 | 0.210 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2005 | 63 | 0.210 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2004 | 36 | 0.210 |
Why?
|
| Vitamins | 1 | 2025 | 92 | 0.210 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2026 | 185 | 0.210 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 2 | 2024 | 11 | 0.200 |
Why?
|
| Dietary Supplements | 1 | 2025 | 152 | 0.200 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2003 | 16 | 0.200 |
Why?
|
| Antioxidants | 1 | 2025 | 236 | 0.200 |
Why?
|
| Abortion, Induced | 2 | 2024 | 168 | 0.200 |
Why?
|
| Multivariate Analysis | 3 | 2026 | 1009 | 0.190 |
Why?
|
| Bupivacaine | 1 | 2003 | 48 | 0.190 |
Why?
|
| Analgesia, Epidural | 1 | 2003 | 42 | 0.190 |
Why?
|
| C-Peptide | 1 | 2023 | 192 | 0.190 |
Why?
|
| United States | 7 | 2026 | 8252 | 0.190 |
Why?
|
| Sex | 1 | 2002 | 6 | 0.180 |
Why?
|
| Labor Stage, First | 1 | 2022 | 3 | 0.180 |
Why?
|
| Fetal Hypoxia | 1 | 2022 | 14 | 0.180 |
Why?
|
| Fetus | 1 | 2023 | 238 | 0.180 |
Why?
|
| Decision Trees | 3 | 2014 | 63 | 0.180 |
Why?
|
| Patient Satisfaction | 2 | 2003 | 513 | 0.180 |
Why?
|
| Checklist | 1 | 2022 | 75 | 0.180 |
Why?
|
| Wechsler Scales | 1 | 2021 | 17 | 0.170 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2014 | 168 | 0.170 |
Why?
|
| Premature Birth | 1 | 2023 | 134 | 0.170 |
Why?
|
| Oxytocin | 1 | 2022 | 73 | 0.170 |
Why?
|
| Thinness | 1 | 2021 | 49 | 0.170 |
Why?
|
| Hypotension | 1 | 2021 | 77 | 0.160 |
Why?
|
| Biomarkers | 2 | 2025 | 2020 | 0.160 |
Why?
|
| Gynecology | 1 | 2002 | 135 | 0.160 |
Why?
|
| Insulin Resistance | 1 | 2022 | 391 | 0.150 |
Why?
|
| Glucose | 1 | 2023 | 704 | 0.150 |
Why?
|
| Goals | 1 | 2020 | 71 | 0.150 |
Why?
|
| Wound Closure Techniques | 1 | 2019 | 15 | 0.150 |
Why?
|
| Risk Factors | 4 | 2026 | 6269 | 0.150 |
Why?
|
| Fetofetal Transfusion | 1 | 2019 | 9 | 0.150 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2019 | 26 | 0.150 |
Why?
|
| Perinatal Care | 1 | 2018 | 23 | 0.140 |
Why?
|
| Pain Management | 1 | 2020 | 194 | 0.140 |
Why?
|
| Prenatal Care | 3 | 2013 | 81 | 0.140 |
Why?
|
| Education, Medical, Continuing | 1 | 2018 | 100 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2019 | 726 | 0.130 |
Why?
|
| Exercise | 2 | 2018 | 382 | 0.130 |
Why?
|
| Decision Support Techniques | 3 | 2015 | 194 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2018 | 250 | 0.120 |
Why?
|
| Counseling | 1 | 2018 | 191 | 0.120 |
Why?
|
| Male | 7 | 2026 | 47195 | 0.120 |
Why?
|
| Fathers | 1 | 2016 | 46 | 0.120 |
Why?
|
| Mouth Mucosa | 1 | 2016 | 71 | 0.120 |
Why?
|
| Genetic Testing | 2 | 2012 | 599 | 0.110 |
Why?
|
| Urolithiasis | 1 | 2015 | 4 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 542 | 0.110 |
Why?
|
| Ureteroscopy | 1 | 2015 | 35 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 3030 | 0.110 |
Why?
|
| Young Adult | 7 | 2025 | 7556 | 0.110 |
Why?
|
| Physicians | 1 | 2002 | 685 | 0.110 |
Why?
|
| Hydrocortisone | 1 | 2016 | 305 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2025 | 2012 | 0.110 |
Why?
|
| Pregnancy Trimester, First | 3 | 2023 | 66 | 0.110 |
Why?
|
| Maternal Mortality | 1 | 2014 | 17 | 0.100 |
Why?
|
| Infant Mortality | 1 | 2014 | 68 | 0.100 |
Why?
|
| Models, Economic | 1 | 2014 | 63 | 0.100 |
Why?
|
| Patient Simulation | 1 | 2013 | 48 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2021 | 4026 | 0.100 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 194 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 602 | 0.100 |
Why?
|
| Rubella | 1 | 2013 | 1 | 0.100 |
Why?
|
| Rubella virus | 1 | 2013 | 1 | 0.100 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2014 | 94 | 0.100 |
Why?
|
| Neural Stem Cells | 1 | 2014 | 73 | 0.100 |
Why?
|
| Weight Loss | 1 | 2015 | 245 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 686 | 0.090 |
Why?
|
| Adolescent | 6 | 2025 | 10127 | 0.090 |
Why?
|
| Antigens, Viral | 1 | 2013 | 123 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 663 | 0.090 |
Why?
|
| Abortion, Habitual | 1 | 2012 | 31 | 0.090 |
Why?
|
| Stents | 1 | 2015 | 440 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1114 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2014 | 280 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2022 | 402 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2014 | 502 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2025 | 1784 | 0.080 |
Why?
|
| Prostate | 1 | 2014 | 434 | 0.080 |
Why?
|
| Echocardiography | 1 | 2014 | 783 | 0.080 |
Why?
|
| Middle Aged | 4 | 2025 | 29494 | 0.070 |
Why?
|
| Age Distribution | 2 | 2007 | 212 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2013 | 450 | 0.070 |
Why?
|
| Time Factors | 3 | 2024 | 5573 | 0.070 |
Why?
|
| Probability | 2 | 2013 | 356 | 0.070 |
Why?
|
| Preimplantation Diagnosis | 1 | 2007 | 6 | 0.070 |
Why?
|
| Live Birth | 1 | 2007 | 23 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2013 | 866 | 0.070 |
Why?
|
| Genetic Counseling | 1 | 2007 | 111 | 0.060 |
Why?
|
| Infertility, Female | 1 | 2007 | 100 | 0.060 |
Why?
|
| Neural Tube Defects | 1 | 2007 | 39 | 0.060 |
Why?
|
| Women's Health | 1 | 2007 | 120 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 281 | 0.060 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2025 | 72 | 0.060 |
Why?
|
| Immunoassay | 1 | 2025 | 102 | 0.060 |
Why?
|
| Postnatal Care | 1 | 2005 | 32 | 0.050 |
Why?
|
| Uterine Rupture | 1 | 2024 | 7 | 0.050 |
Why?
|
| Markov Chains | 1 | 2005 | 147 | 0.050 |
Why?
|
| Chorioamnionitis | 1 | 2024 | 23 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2013 | 1123 | 0.050 |
Why?
|
| Anesthesia, Obstetrical | 1 | 2003 | 31 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 419 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 62 | 0.050 |
Why?
|
| Parity | 1 | 2003 | 97 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 195 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 666 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2022 | 58 | 0.050 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2022 | 30 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 1841 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2014 | 2687 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 608 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 187 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 793 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2003 | 401 | 0.040 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2021 | 39 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 359 | 0.040 |
Why?
|
| Ibuprofen | 1 | 2020 | 35 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 62 | 0.040 |
Why?
|
| Acetaminophen | 1 | 2020 | 63 | 0.040 |
Why?
|
| Incidence | 1 | 2005 | 1786 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 1391 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 345 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 1612 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2022 | 914 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 2598 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 913 | 0.030 |
Why?
|
| Length of Stay | 1 | 2020 | 875 | 0.030 |
Why?
|
| Suburban Population | 1 | 2016 | 6 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1129 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2016 | 40 | 0.030 |
Why?
|
| Phenotype | 1 | 2022 | 2653 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1946 | 0.030 |
Why?
|
| Saliva | 1 | 2016 | 134 | 0.030 |
Why?
|
| Foreign-Body Migration | 1 | 2015 | 32 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 4041 | 0.030 |
Why?
|
| Rural Population | 1 | 2016 | 193 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 249 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2007 | 9750 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 81 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2014 | 102 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2016 | 384 | 0.020 |
Why?
|
| Embryo Loss | 1 | 2012 | 5 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2012 | 70 | 0.020 |
Why?
|
| Cost Savings | 1 | 2012 | 68 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 970 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 352 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2054 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1790 | 0.020 |
Why?
|
| Urban Health Services | 1 | 2007 | 44 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 4126 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2007 | 202 | 0.010 |
Why?
|
| Illinois | 1 | 2007 | 524 | 0.010 |
Why?
|
| Algorithms | 1 | 2012 | 2001 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3611 | 0.010 |
Why?
|
| Child | 1 | 2013 | 7730 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 28950 | 0.010 |
Why?
|